{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T02:52:23Z","timestamp":1792378343032,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41401-025-01668-7","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T15:01:44Z","timestamp":1762441304000},"page":"932-945","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mup3 ameliorates the dysregulation of glucose and lipid metabolism in MAFLD"],"prefix":"10.1038","volume":"47","author":[{"given":"Xiao-min","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-ya","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-rui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-ting","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-bing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-bing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"1668_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"key":"1668_CR2","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","volume":"142","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American gastroenterological association, American association for the study of liver diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592\u2013609.","journal-title":"Gastroenterology"},{"key":"1668_CR3","doi-asserted-by":"publisher","first-page":"323rv1","DOI":"10.1126\/scitranslmed.aad8390","volume":"8","author":"JA Woo Baidal","year":"2016","unstructured":"Woo Baidal JA, Lavine JE. The intersection of nonalcoholic fatty liver disease and obesity. Sci Transl Med. 2016;8:323rv1.","journal-title":"Sci Transl Med"},{"key":"1668_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","volume":"27","author":"VT Samuel","year":"2018","unstructured":"Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab. 2018;27:22\u201341.","journal-title":"Cell Metab"},{"key":"1668_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","volume":"75","author":"P Golabi","year":"2021","unstructured":"Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. Burden of non-alcoholic fatty liver disease in Asia, the middle East and north Africa: data from global burden of disease 2009-2019. J Hepatol. 2021;75:795\u2013809.","journal-title":"J Hepatol"},{"key":"1668_CR6","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1007\/s00125-023-05966-9","volume":"66","author":"CR Andreasen","year":"2023","unstructured":"Andreasen CR, Andersen A, Vilsb\u00f8ll T. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Diabetologia. 2023;66:1846\u201358.","journal-title":"Diabetologia"},{"key":"1668_CR7","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836\u201346.","journal-title":"Hepatology"},{"key":"1668_CR8","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322.","journal-title":"Nat Med"},{"key":"1668_CR9","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.7150\/ijbs.27173","volume":"14","author":"X Huang","year":"2018","unstructured":"Huang X, Liu G, Guo J, Su Z. The PI3K\/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14:1483\u201396.","journal-title":"Int J Biol Sci"},{"key":"1668_CR10","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537\u201364.","journal-title":"Cell"},{"key":"1668_CR11","first-page":"921","volume":"110","author":"P Kasper","year":"2021","unstructured":"Kasper P, Martin A, Lang S, K\u00fctting F, Goeser T, Demir M, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol J Ger Card Soc. 2021;110:921\u201337.","journal-title":"Clin Res Cardiol J Ger Card Soc"},{"key":"1668_CR12","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3390\/jcm11040968","volume":"11","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-Peralta F. Non-alcoholic fatty liver disease and risk of macro- and microvascular complications in patients with type 2 diabetes. J Clin Med. 2022;11:968.","journal-title":"J Clin Med."},{"key":"1668_CR13","doi-asserted-by":"publisher","first-page":"6613827","DOI":"10.1155\/2021\/6613827","volume":"2021","author":"M Maru\u0161i\u0107","year":"2021","unstructured":"Maru\u0161i\u0107 M, Pai\u0107 M, Knobloch M, Liberati Pr\u0161o AM. NAFLD, insulin resistance, and diabetes mellitus type 2. Can J Gastroenterol Hepatol. 2021;2021:6613827.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1668_CR14","doi-asserted-by":"publisher","first-page":"32345","DOI":"10.1074\/jbc.M313478200","volume":"279","author":"VT Samuel","year":"2004","unstructured":"Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345\u201353.","journal-title":"J Biol Chem"},{"key":"1668_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17195-y","volume":"12","author":"S Greve","year":"2022","unstructured":"Greve S, Kuhn GA, Saenz-de-Juano MD, Ghosh A, von Meyenn F, Giller K. The major urinary protein gene cluster knockout mouse as a novel model for translational metabolism research. Sci Rep. 2022;12:13161.","journal-title":"Sci Rep"},{"key":"1668_CR16","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3390\/nu12030815","volume":"12","author":"K Pallauf","year":"2020","unstructured":"Pallauf K, G\u00fcnther I, Chin D, Rimbach G. In contrast to dietary restriction, application of resveratrol in mice does not alter mouse major urinary protein expression. Nutrients. 2020;12:815.","journal-title":"Nutrients"},{"key":"1668_CR17","doi-asserted-by":"publisher","first-page":"11152","DOI":"10.1074\/jbc.M900754200","volume":"284","author":"Y Zhou","year":"2009","unstructured":"Zhou Y, Jiang L, Rui L. Identification of MUP1 as a regulator for glucose and lipid metabolism in mice. J Biol Chem. 2009;284:11152\u20139.","journal-title":"J Biol Chem"},{"key":"1668_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106585","volume":"187","author":"R Gao","year":"2023","unstructured":"Gao R, Wang H, Li T, Wang J, Ren Z, Cai N, et al. Secreted MUP1 that reduced under ER stress attenuates ER stress induced insulin resistance through suppressing protein synthesis in hepatocytes. Pharmacol Res. 2023;187:106585.","journal-title":"Pharmacol Res"},{"key":"1668_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2367342","volume":"16","author":"H Zhang","year":"2024","unstructured":"Zhang H, Li C, Han L, Xiao Y, Bian J, Liu C, et al. MUP1 mediates urolithin A alleviation of chronic alcohol-related liver disease via gut-microbiota-liver axis. Gut Microbes. 2024;16:2367342.","journal-title":"Gut Microbes"},{"key":"1668_CR20","doi-asserted-by":"publisher","first-page":"9687","DOI":"10.3390\/ijms23179687","volume":"23","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wu X, Xu M, Yue T, Ling P, Fang T, et al. Comparative proteomic pnalysis of liver tissues and serum in db\/db mice. Int J Mol Sci. 2022;23:9687.","journal-title":"Int J Mol Sci"},{"key":"1668_CR21","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0021-9258(19)86039-8","volume":"255","author":"PR Szoka","year":"1980","unstructured":"Szoka PR, Gallagher JF, Held WA. In vitro synthesis and characterization of precursors to the mouse major urinary proteins. J Biol Chem. 1980;255:1367\u201373.","journal-title":"J Biol Chem"},{"key":"1668_CR22","doi-asserted-by":"publisher","first-page":"5524","DOI":"10.1073\/pnas.0305300101","volume":"101","author":"JM Dhahbi","year":"2004","unstructured":"Dhahbi JM, Kim HJ, Mote PL, Beaver RJ, Spindler SR. Temporal linkage between the phenotypic and genomic responses to caloric restriction. Proc Natl Acad Sci USA. 2004;101:5524\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1668_CR23","first-page":"20130101","volume":"280","author":"K Giller","year":"2013","unstructured":"Giller K, Huebbe P, Doering F, Pallauf K, Rimbach G. Major urinary protein 5, a scent communication protein, is regulated by dietary restriction and subsequent re-feeding in mice. Proc Biol Sci. 2013;280:20130101.","journal-title":"Proc Biol Sci"},{"key":"1668_CR24","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.bbrc.2015.03.155","volume":"460","author":"CC Chen","year":"2015","unstructured":"Chen CC, Lee TY, Kwok CF, Hsu YP, Shih KC, Lin YJ, et al. Major urinary protein 1 interacts with cannabinoid receptor type 1 in fatty acid-induced hepatic insulin resistance in a mouse hepatocyte model. Biochem Biophys Res Commun. 2015;460:1063\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1668_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jfma.2019.03.014","volume":"119","author":"JF Huang","year":"2020","unstructured":"Huang JF, Tsai PC, Yeh ML, Huang CF, Huang CI, Hsieh MH, et al. Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis. J Formos Med Assoc. 2020;119:89\u201396.","journal-title":"J Formos Med Assoc"},{"key":"1668_CR26","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s42255-023-00896-7","volume":"5","author":"Z Yao","year":"2023","unstructured":"Yao Z, Gong Y, Chen W, Shao S, Song Y, Guo H, et al. Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice. Nat Metab. 2023;5:1706\u201325.","journal-title":"Nat Metab"},{"key":"1668_CR27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrendo.2017.56","volume":"13","author":"RCR Meex","year":"2017","unstructured":"Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13:509\u201320.","journal-title":"Nat Rev Endocrinol"},{"key":"1668_CR28","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nm.2686","volume":"18","author":"M Lu","year":"2012","unstructured":"Lu M, Wan M, Leavens KF, Chu Q, Monks BR, Fernandez S, et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med. 2012;18:388\u201395.","journal-title":"Nat Med"},{"key":"1668_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cmet.2008.06.006","volume":"8","author":"XC Dong","year":"2008","unstructured":"Dong XC, Copps KD, Guo S, Li Y, Kollipara R, DePinho RA, et al. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab. 2008;8:65\u201376.","journal-title":"Cell Metab"},{"key":"1668_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","volume":"49","author":"E Cobbina","year":"2017","unstructured":"Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197\u2013211.","journal-title":"Drug Metab Rev"},{"key":"1668_CR31","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1210\/er.2019-00034","volume":"40","author":"MJ Watt","year":"2019","unstructured":"Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019;40:1367\u201393.","journal-title":"Endocr Rev"},{"key":"1668_CR32","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1111\/j.1460-9568.2006.05244.x","volume":"24","author":"J Xia","year":"2006","unstructured":"Xia J, Sellers LA, Oxley D, Smith T, Emson P, Keverne EB. Urinary pheromones promote ERK\/Akt phosphorylation, regeneration and survival of vomeronasal (V2R) neurons. Eur J Neurosci. 2006;24:3333\u201342.","journal-title":"Eur J Neurosci"},{"key":"1668_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1146\/annurev.physiol.67.031103.154845","volume":"67","author":"M Gekle","year":"2005","unstructured":"Gekle M. Renal tubule albumin transport. Annu Rev Physiol. 2005;67:573\u201394.","journal-title":"Annu Rev Physiol"},{"key":"1668_CR34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jhep.2015.08.021","volume":"64","author":"J Hu","year":"2016","unstructured":"Hu J, Zhu XH, Zhang XJ, Wang PX, Zhang R, Zhang P, et al. Targeting TRAF3 signaling protects against hepatic ischemia\/reperfusions injury. J Hepatol. 2016;64:146\u201359.","journal-title":"J Hepatol"},{"key":"1668_CR35","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.2174\/1389450116666150804110412","volume":"18","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Zhang XJ, Li H. Targeting interferon regulatory factor for cardiometabolic diseases: opportunities and challenges. Curr Drug Targets. 2017;18:1754\u201378.","journal-title":"Curr Drug Targets"},{"key":"1668_CR36","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.tem.2019.08.006","volume":"30","author":"Z Chen","year":"2019","unstructured":"Chen Z, Yu Y, Cai J, Li H. Emerging molecular targets for treatment of nonalcoholic fatty liver disease. Trends Endocrinol Metab TEM. 2019;30:903\u201314.","journal-title":"Trends Endocrinol Metab TEM"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01668-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01668-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01668-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T22:26:10Z","timestamp":1774477570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01668-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1668"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01668-7","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}